Log in to search using one of your social media accounts:


PhRMA, member companies and NIH create public-private partnership for immuno-oncology

The rapid pace of scientific advances has helped usher in anew era of medicine for cancer patients over the last decade. This morning, the National Institutes of Health (NIH) took asignificant step in advancing this new era by partnering with PhRMA and nine of its member companies to create the Partnership for Accelerating Cancer Therapies (PACT), a five-year research collaboration totaling $215 million as part of the Cancer Moonshot initiative. This public-private partnership will be managed by the Foundation for the National Institutes of Health.
Source: The Catalyst - Category: Pharmaceuticals Tags: Research and Development cancer Source Type: news

Related Links:

UR Medicine ’s Wilmot Cancer Institute will be among the first sites in the world to offer CAR T-cell therapy —a new type of immunotherapy—to adults with aggressive lymphoma. The engineered gene therapy has been described as a revolutionary “living drug” and one of the most powerful cancer treatments to emerge in recent years.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: Source Type: news
Funding Opportunity RFA-CA-17-044 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this Funding Opportunity Announcement (FOA) is to create a U24 Coordinating Center that will integrate and facilitate trans-disciplinary research across the Drug Resistance and Sensitivity Centers (DRSCs), established under an earlier released RFA-CA-17-009 for U54 specialized centers. The DRSCs are designed to target the following area designated as a scientific priority by th...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Authors: Kou B, Liu W, Xu X, Yang Y, Yi Q, Guo F, Li J, Zhou J, Kou Q Abstract Tetrandrine, a bisbenzylisoquinoline alkaloid isolated from the roots of Stephania tetrandra is a traditional Chinese medicine and exerts anticancer capacity in various types of cancers. Previous studies have shown that tetrandrine induces apoptosis in bladder cancer cells via activation of the caspase cascade. However, the underlying mechanism has not yet been reported. Autophagy is a cellular process involved in the degradation of broken proteins and aging organelles to maintain homeostasis. Recent studies indicate that autophagy is im...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
In conclusion, these results indicate that capsaicin may exert therapeutic benefits as an adjunct to current cancer therapies but not as an independent anticancer agent. PMID: 29048662 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
In conclusion, juglone potentiated TRAIL‑induced apoptosis in melanoma cells, and these effects were partially mediated through the ROS‑p38‑p53 pathway. These findings suggested that juglone may be a potential sensitizer for TRAIL therapy in the treatment of melanoma. PMID: 29039537 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Skinner KE, Fernandes AW, Walker MS, Pavilack M, VanderWalde A Abstract AIMS: To assess healthcare costs during treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and following disease progression in patients with advanced non-small cell lung cancer (NSCLC). METHODS: A retrospective analysis of medical records of US community oncology practices was conducted. Eligible patients had advanced NSCLC (stage IIIB/IV) diagnosed between January 1, 2008 and January 1, 2015, initiated treatment with erlotinib or afatinib (first-line or second-line), and had disease progressi...
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
The company is working on a therapy for pancreatic cancer using nanotechnology.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
AbstractKi67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive ta...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
In this study we discovered that the MLKL-modifying compound necrosulfonamide cross-links cysteine 86 of human MLKL to cysteine 32 of the thiol oxidoreductase thioredoxin-1 (Trx1). Recombinant Trx1 preferentially binds to monomeric MLKL and blocks MLKL disulfide bond formation and polymerization in vitro. Inhibition of MLKL polymer formation requires the reducing activity of Trx1. Importantly, shRNA-mediated knockdown of Trx1 promotes MLKL polymerization and sensitizes cells to necroptosis. Furthermore, pharmacological inhibition of Trx1 with compound PX-12 induces necroptosis in multiple cancer cell lines. Altogether, the...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Signal Transduction Source Type: research
Publication date: 1 January 2018 Source:Colloids and Surfaces B: Biointerfaces, Volume 161 Author(s): Pralay Maity, Madhubanti Bepari, Ananya Pradhan, Rathindranath Baral, Sumita Roy, Sujata Maiti Choudhury In the present study, we demonstrate a simple, cost-effective and eco-friendly method for biogenic synthesis of silver nanoparticles (AgNPCGs) using ethanolic extract of Calotropis gigantea latex. Attempts were made to characterize these biogenic silver nanoparticles AgNPCGs and also to test its cytotoxic, anti-neoplastic and apoptotic potential through the induction of oxidative stress, mitochondrial dysfunction. AgNP...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | National Institutes of Health (NIH) | Partnerships | Pharmaceuticals